Patents Assigned to Chinese Academy of Medical Science
-
Patent number: 12006551Abstract: A miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The miRNA23 cluster is used in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3?-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.Type: GrantFiled: July 15, 2022Date of Patent: June 11, 2024Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking UniversityInventors: Rui Liu, Zhuorong Li, Li Zeng, Ting Sun, Mimin Liu, Junxia Zhang
-
Patent number: 11993603Abstract: A medicament with excellent JAK kinase (Janus Kinase) inhibitory activity can be used to prevent, treat and/or improve an autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like). The present invention also provides a pharmaceutically acceptable composition containing the compound and a method for preparing these compounds.Type: GrantFiled: September 5, 2019Date of Patent: May 28, 2024Assignees: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE, CHINA PARMACEUTICAL UNIVERSITYInventors: Tiantai Zhang, Dayong Zhang, Chengjuan Chen, Yuan Yin, Runan Yu, Lei Shu
-
Patent number: 11974969Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.Type: GrantFiled: March 29, 2019Date of Patent: May 7, 2024Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Chengyu Jiang, Yuhao Qin, Xiaoyun Li, Cong Zhang
-
Patent number: 11976300Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.Type: GrantFiled: April 11, 2019Date of Patent: May 7, 2024Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Haiyan Xu, Jian Liu, Tao Wang, Bing Han, Jie Meng, Tao Wen
-
Patent number: 11939307Abstract: Disclosed are a benzyl piperazine compound, a preparation method there for and an application thereof in an antivirus. The benzyl piperazine compound has a structure represented by the following general formula(I). It is proven by experiments that the benzyl piperazine compound not only has significant antiviral activity, but also has the advantages of low cytotoxicity, a high selectivity index and soon.Type: GrantFiled: November 29, 2019Date of Patent: March 26, 2024Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yanping Li, Zhuorong Li, Zonggen Peng, Xinbei Jiang, Yixuan Wang, Jianrui Li, Jiali Tan
-
Patent number: 11925559Abstract: A method for in vitro simulation and evaluation of platelet adhesion in blood-contacting medical devices is disclosed, including the following steps: (1) using a glycerin aqueous solution with a mass percentage concentration of 40% in an extracorporeal circulation circuit to simulate a viscosity and hydrodynamic characteristics of blood, and adding fluorescent particles with a diameter of 3 ?m to 5 ?m to the solution to simulate platelets; (2) after the solution circulates in the circuit for a specified time period, removing flow passage components of a tested device, and observing the deposition of the fluorescent particles on a blood-contacting surface inside the device by naked eyes and photographs; and (3) using laser-induced fluorescence (LIF) technique to apply laser light on a device surface deposited with the fluorescent particles and in contact with blood, and using charge-coupled device (CCD) camera imaging to photograph the aggregation and adhesion of laser-induced fluorescent particles.Type: GrantFiled: May 21, 2020Date of Patent: March 12, 2024Assignee: FUWAI HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES, SHENZHENInventors: Shengshou Hu, Guangmao Liu
-
Publication number: 20240062881Abstract: A system for predicting microsatellite instability and a construction method thereof, a terminal device and a medium are provided. Target image information, pathological specimen information and clinical data information of a user to be predicted are acquired by an acquisition module in the system for predicting microsatellite instability; a radiomics signature is generated according to the target image information, and a pathomics signature is generated according to the pathological specimen information, by a signature generation module, based on a pre-trained MSI-H/dMMR multi-omics signature model; and MSI-H/dMMR prediction results are generated according to the radiomics signature, the pathomics signature and the clinical data information, by a prediction generation module, based on a pre-trained MSI-H/dMMR prediction model.Type: ApplicationFiled: October 31, 2023Publication date: February 22, 2024Applicant: CANCER HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Qing ZHAO, Hongxia ZHONG, Hongmei ZHANG, Xinming ZHAO
-
Publication number: 20240062915Abstract: A system for predicting therapy resistance and its molecular mechanisms in rectal cancer before treatment is provided. The system includes a feature extraction device, a collection device, a signature construction device and a prediction device. The system can predict responses to neoadjuvant therapy in patients before treatment, analyze patients who are resistant to rectal cancer therapy and their underlying molecular mechanism, thereby enabling personalized therapy for patients who are resistant to rectal cancer therapy. The system has important clinical significance in improving the overall survival of rectal cancer patients.Type: ApplicationFiled: October 31, 2023Publication date: February 22, 2024Applicant: CANCER HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Qing ZHAO, Xu GUAN, Enrui LIU, Ran WEI, Xiaoxiao SONG
-
Publication number: 20240062904Abstract: A tumor diagnosis system and a construction method thereof, a terminal device and a storage medium are provided, wherein a radiomics signature is obtained by a radiomics signature-generation module in the tumor diagnosis system according to target radiomics information and clinical data information, based on a pre-trained radiomics signature model; a first classification comprehensive diagnosis result is obtained by a benign and malignant comprehensive classification module according to a ambient situation of a lesion outside an intestinal wall, the clinical data information and a first radiomics signature, based on a pre-trained first classification comprehensive diagnosis model; a second classification comprehensive diagnosis result is generated through a malignant focus sub-classification module based on a pre-trained second classification comprehensive diagnosis model, if the first classification comprehensive diagnosis result includes high-risk malignant information; and a final diagnosis result is obtaiType: ApplicationFiled: October 31, 2023Publication date: February 22, 2024Applicant: CANCER HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Qing ZHAO, Hongmei ZHANG, Xinming ZHAO
-
Publication number: 20240058432Abstract: Provided are an HPV chimeric protein and a use thereof. The HPV chimeric protein of the present invention comprises an HPV58 L1 protein or a mutant thereof and a polypeptide derived from a HPV16 L2 protein and inserted into a surface region of the HPV58 L1 protein or the mutant thereof, or consists of the polypeptide, wherein an amino acid sequence of the HPV58 L1 protein is as shown in SEQ ID No. 1 and an amino acid sequence of the HPV16 L2 protein is as shown in SEQ ID No. 2.Type: ApplicationFiled: September 26, 2021Publication date: February 22, 2024Applicant: Institute of Basic Medical Sciences, Chinese Academy of Medical SciencesInventors: Xuemei XU, Zhirong WANG, Mingrao MA, Ting ZHANG
-
Publication number: 20240041814Abstract: The present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. The present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the present disclosure sets forth use of retinol and ATRA as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the ATRA can effectively delay the progression of the pneumoconiosis. Therefore, the present disclosure first sets forth use of the ATRA as a medicament for treating the pneumoconiosis.Type: ApplicationFiled: January 19, 2023Publication date: February 8, 2024Applicant: Institute of Basic Medical Sciences of Chinese Academy of Medical SciencesInventors: Jing WANG, Meiyue SONG, Jiaxin WANG
-
Patent number: 11883452Abstract: An application of a combination or composition of Radix et Rhizoma Notoginseng and aspirin in the preparation of a drug for preventing and treating cardiovascular and cerebrovascular diseases, the combination or composition being as follows: the dose range of Radix et Rhizoma Notoginseng is 25-500 mg/d, and the dose range of aspirin is 20-700 mg/d. The Radix et Rhizoma Notoginseng comprises commercially available products, Radix et Rhizoma Notoginseng, an extract prepared from Radix et Rhizoma Notoginseng, an active ingredient of Radix et Rhizoma Notoginseng and a preparation of Radix et Rhizoma Notoginseng, and so on. Radix et Rhizoma Notoginseng and aspirin have a synergistic effect, while reducing gastric mucosal damage caused by aspirin.Type: GrantFiled: December 13, 2017Date of Patent: January 30, 2024Assignee: CHINESE ACADEMY OF MEDICAL SCIENCES INSTITUTE OF MEDICINAL PLANT DEVELOPMENTInventors: Xiaobo Sun, Xiangbao Meng, Guibo Sun, Huibo Xu
-
Publication number: 20230406938Abstract: The present disclosure provides use of an Fc?RIII inhibitor for treating pulmonary fibrosis, and belongs to the technical field of biomedicine. Results indicate that Fc?RIII mediates macrophage phagocytosis of silica particles, Fc?RIII knockout can effectively relieve pulmonary inflammatory response and fibrotic lesions in mice with silicosis, and further intratracheal administration of an anti-Fc?RIII antibody significantly delays disease progression of mice at fibrosis phase. Therefore, the present disclosure first sets forth that the Fc?RIII inhibitors can be used for treating pulmonary fibrosis, which is of importance to the screening of new drugs and provides a new idea for treatment of pulmonary fibrosis.Type: ApplicationFiled: October 3, 2022Publication date: December 21, 2023Applicant: Institute of Basic Medical Sciences of Chinese Academy of Medical SciencesInventors: Jing Wang, Tiantian Zhang, Xianmei Qi, Xiaona Li
-
Publication number: 20230408531Abstract: The present disclosure provides use of malic enzyme 2 (ME2) in preparation of a diagnostic reagent or a medicament for silicosis or pulmonary fibrosis-related diseases, and belongs to the technical fields of medical treatment and medicine. Research results of the present disclosure show that ME2 knockout significantly alleviates inflammatory response and fibrotic lesions in mice with silicosis. Based on the above research results, the present disclosure provides use of ME2 in treatment of pulmonary inflammatory responses and pulmonary fibrotic lesions of silicosis or pulmonary fibrosis-related diseases. Expression of ME2 is inhibited to alleviate the inflammatory response and fibrotic lesions of the silicosis, providing support for exploring a targeted drug for treating pulmonary inflammatory responses and pulmonary fibrosis of silicosis or pulmonary fibrosis-related diseases.Type: ApplicationFiled: September 6, 2022Publication date: December 21, 2023Applicant: Institute of Basic Medical Sciences of Chinese Academy of Medical SciencesInventors: Jing WANG, Tiantian ZHANG, Youliang SUN, Xianmei QI
-
Patent number: 11827612Abstract: The present disclosure is related to the field of enzyme inhibitors, and in particular to a hydroxamic acid derivative, a method for producing the same and use thereof. The hydroxamic acid group of the hydroxamic acid derivative can be chelated with zinc ions in the LpxC active area, and the derivative has a hydrophobic side chain which can bind to hydrophic channels in the enzyme LpxC. These guarantee that the hydroxamic acid derivative has good bactericidal activity against Gram-negative bacteria and low toxicity. The present disclosure also provides a method for producing the hydroxamic acid derivative, which requires a shorter reaction time and can provide the derivative with a high yield.Type: GrantFiled: September 16, 2020Date of Patent: November 28, 2023Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yucheng Wang, Xuefu You, Juxian Wang, Xiaonan Du, Minghua Wang, Mei Zhu, Guoning Zhang
-
Publication number: 20230364064Abstract: The present disclosure is directed to methods of administering tetrandrine in combination with all-trans retinoic acid (ATRA) for treating pneumoconiosis. Administration of ATRA in combination with tetrandrine can effectively alleviate the progression of silicosis: impaired cardiopulmonary functions of mice with silicosis are improved significantly, including inspiratory capacity, quasi-static compliance, and right ventricular pressure; concentrations of inflammatory factors IL-1? and IL-6 in bronchoalveolar lavage fluids of mice with silicosis decrease, and the number of inflammatory cells is reduced; levels of fibrosis factors FN-1 and Col-I decrease, fibrous foci are reduced, and pathological degree is alleviated. Moreover, combination therapy with ATRA in combination with tetrandrine shows a superiority of combined administration in terms of cardiopulmonary function, inflammation and fibrosis, and exhibits a better effect than administration of tetrandrine alone.Type: ApplicationFiled: December 9, 2022Publication date: November 16, 2023Applicant: Institute of Basic Medical Sciences of Chinese Academy of Medical SciencesInventors: Jing WANG, Meiyue SONG, Jiaxin WANG
-
Patent number: 11771660Abstract: A flavonoid polyphenol drug self-emulsifying composition based on a flavonoid polyphenol drug-phospholipid complex being used as an intermediate, the composition comprising a flavonoid polyphenol drug-phospholipid complex, an oil phase, an emulsifier and a co-emulsifier, the flavonoid polyphenol drug comprising one or more selected from baicalein, proanthocyanidin, quercetin, curcumin and resveratrol. The described self-emulsifying composition has the beneficial effects of good stability, a high amount of drug loading, high bioavailability, and so on.Type: GrantFiled: April 8, 2020Date of Patent: October 3, 2023Assignees: BEIJING WEHAND-BIO PHARMACEUTICAL CO., LTD., INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCE & PEKING UNION MEDICAL COLLEGEInventors: Yuling Liu, Hengfeng Liao, Yue Gao, Wujun Dong, Zhihua Liu, Bangyuan Wang, Yun Zhang, Yu Feng, Junzhuo Zhou, Lu Liu, Jun Ye, Yanfang Yang, Xuejun Xia
-
MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME
Publication number: 20230293570Abstract: Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.Type: ApplicationFiled: September 29, 2022Publication date: September 21, 2023Applicant: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Chengyu JIANG, Jianchao DU, Zhu LIANG, Jiantao XU, Yan ZHAO -
Patent number: 11725006Abstract: An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity.Type: GrantFiled: October 17, 2019Date of Patent: August 15, 2023Assignee: INSTITUTE OF MATERIA MEDIC, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Hailin Qin, Lianqiu Wu, Xiang Li, Haijing Zhang, Li Song, Huachen Song, Anjun Deng, Xiaonan Tang, Zhihui Zhang, Xiang Li, Zhihong Li
-
Publication number: 20230227444Abstract: The present invention relates to a compound as shown in general formula (I) below (in formula (I), each of R1 and R2 independently represents a hydrogen atom or a C1-10 linear or branched alkyl optionally having a substituent, or the two together form a cycloalkyl with 3 to 8 ring carbon atoms; each of R3 and R4 independently represents a hydrogen atom or a C1-10 linear or branched alkyl optionally having a substituent or a C6-12 aryl optionally having a substituent, or the two together form a cycloalky with 3 to 8 ring carbon atoms; X represents C or N; and Y represents a linear or branched alkenyl or alkynyl with 2 to 6 carbon atoms and optionally having a substituent, or carboxyl). The compound has good antibacterial properties against bacteria, especially gram-negative bacteria, has low drug resistance, and has good prospects for the effective treatment of various conditions.Type: ApplicationFiled: April 30, 2021Publication date: July 20, 2023Applicants: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES, GUANGZHOU HC PHARMACEUTICAL CO. LTDInventors: Danqing SONG, Sheng TANG, Xuefu YOU, Zhiwen LI, Yanxiang WANG, Xi LU, Yinghong LI, Xinxin HU, Zhihao GUO, Xiukun WANG